Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 7/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 3/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22487747 | 0.88 | XDH (0.42) | GRM1XDHKDM4EALDH1A1HPGD | |
| SCHEMBL22487927 | 0.79 | GSK3B (0.41) | GRM1PDE2AXDHCYP17A1NPSR1 | |
| SCHEMBL22488037 | 0.76 | HPGD (0.39) | GRM1XDHKDM4EALDH1A1HPGD | |
| SCHEMBL5432319 | 0.71 | GRM1 (0.42) | GRM1PDE2AGRM5 | |
| SCHEMBL5437218 | 0.66 | MEN1 (0.46) | GRM1XDHGRM5KDM4EHCAR1 | |
| SCHEMBL5429761 | 0.65 | POLB (0.47) | GRM1PDE2AXDHGRM5ALDH1A1 | |
| SCHEMBL14336690 | 0.64 | CCR1 (0.35) | BRAF | |
| SCHEMBL22487750 | 0.63 | HPGD (0.42) | XDHKDM4EALDH1A1HPGDHTT | |
| SCHEMBL11922119 | 0.62 | L3MBTL1 (0.35) | — | |
| SCHEMBL11005247 | 0.60 | BRAF (0.41) | BRAFNPSR1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | GRM1 4660/4885PDE2A 1853/4885BRAF 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.